Polaris Partners

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By harnessing self-supervised learning and integrating diverse human multimodal data, the company aims to enhance the precision and effectiveness of immunotherapies. This approach enables the development of more personalized cancer treatments, contributing to the advancement of targeted therapies in oncology.

Livara Health is a provider of non-operative, personalized treatment for musculoskeletal conditions, focusing specifically on back and neck problems. The company has developed an orthopedic care management platform that offers a data-driven, non-invasive back pain program. This program assesses patients' needs and customizes a comprehensive six-week treatment plan aimed at delivering relief. Patients receive physical therapy coaching, which can be accessed both online and onsite, to support their progress throughout the program. Livara Health's approach allows individuals to manage their musculoskeletal issues effectively without the need for surgical intervention.

Capstan Therapeutics is a biotechnology company focused on advancing precision in vivo cell engineering to create therapeutics for various disease categories that have unmet or underserved clinical needs. The company specializes in expanding the therapeutic potential of RNA-based therapies through proprietary targeted delivery systems. Their platform utilizes targeted lipid nanoparticles to enhance off-the-shelf immunotherapies, providing tight control over dosage and activity of engineered cells. This approach aims to develop transformative products for conditions such as oncology, fibrosis, and inflammation-related diseases.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Cohere Health, Inc. is a healthcare technology company based in Boston, Massachusetts, founded in 2019. The company specializes in developing a platform that enhances collaboration among healthcare stakeholders, including patients, providers, and payers. Cohere Health focuses on improving the efficiency and effectiveness of healthcare delivery by simplifying complex processes through technology. Its primary offering is an intelligent prior authorization solution that is configurable to meet the specific needs of different health plans. This solution can be implemented as a fully outsourced utilization management service, utilizing artificial intelligence, machine learning, and real-time analytics to automate the prior authorization process. By doing so, Cohere Health aims to facilitate seamless communication and guide quality care throughout the patient journey, ultimately improving patient outcomes.

UpDoc is a technology-enabled services firm that offers the world's first unique conversational AI platform for autonomous prescription management.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra focuses on creating orally administered dosage forms that provide sustained drug release for extended periods, ranging from a week to a month, while temporarily residing in the stomach. The company aims to address various therapeutic areas, including Alzheimer's, cardiovascular and metabolic diseases, psychiatric disorders, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By developing these innovative therapies, Lyndra seeks to enhance medication adherence, improve health outcomes, and ultimately reduce healthcare costs.

Seismic Therapeutic is a biotechnology company focused on advancing immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its proprietary IMPACT™ platform, Seismic Therapeutic addresses critical challenges in the development of biologics by combining machine learning with structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies for patients more efficiently. The company is developing a pipeline of biologics specifically targeting adaptive immune system dysregulation to treat various autoimmune diseases.

Sovato Health specializes in remote surgical access, offering a platform that connects skilled surgeons with patients in underserved areas. This platform integrates people, systems, tools, data, and business models to ensure safe, scalable, and sustainable remote surgical procedures.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Tausight, Inc. is a software company founded in 2018 and headquartered in Sudbury, Massachusetts, with an additional office in San Francisco, California. The company focuses on mitigating healthcare cyber incidents related to patient data theft, addressing a critical need for chief information officers and chief information security officers in the healthcare sector. Tausight's software employs machine learning techniques to enhance the confidentiality, integrity, and availability of patient health information (PHI). By implementing a proactive risk management approach, the software aims to improve patient care, clinician satisfaction, regulatory compliance, and foster innovation within healthcare organizations.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

Crossbow Therapeutics is a biotechnology company focused on developing innovative cancer treatments. The company engineers antibodies to mimic T-cells, which are essential components of the immune system, aiming to enhance the quality of life for cancer patients. Their next-generation immunotherapies are designed to target previously unreachable cancer cell proteins with high precision, offering an efficient and selective approach to cancer treatment. By unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies, Crossbow Therapeutics seeks to dramatically expand the capabilities of antibody therapy across various cancer types, ultimately improving patient outcomes.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra focuses on creating orally administered dosage forms that provide sustained drug release for extended periods, ranging from a week to a month, while temporarily residing in the stomach. The company aims to address various therapeutic areas, including Alzheimer's, cardiovascular and metabolic diseases, psychiatric disorders, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By developing these innovative therapies, Lyndra seeks to enhance medication adherence, improve health outcomes, and ultimately reduce healthcare costs.

Candesant Biomedical, Incorporated is a medical device company focused on developing innovative solutions for excessive sweating and hyperhidrosis. Founded in 2015 and based in San Francisco, California, the company offers a proprietary device known as CDX-101, which utilizes water-activated technology to target and inactivate active sweat glands without causing discomfort to patients. The technology operates on the principle that alkali metals generate energy upon contact with water, allowing for precise energy delivery to the specific areas where sweat glands are most active. This approach not only aims to reduce excessive sweating but also helps inhibit bacterial growth associated with hyperhidrosis, providing a significant improvement in the quality of life for affected individuals.

Larkspur Biosciences is a biotechnology company dedicated to developing precision immunotherapies aimed at enhancing cancer treatment. The company focuses on understanding how tumors manipulate the immune system and seeks to address these challenges by targeting specific molecular characteristics of patient populations. Larkspur's innovative approach is designed to foster a robust and sustained immune response, particularly in colorectal cancer, while also exploring applications for other cancers. By aligning its therapies with the unique molecular profiles of tumors, Larkspur aims to improve treatment outcomes for patients facing the complexities of cancer.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis employs proprietary platforms and biomarkers to create precision medicines that target genetically validated disease-causing alterations. The company’s pipeline includes innovative treatments aimed at specific subtypes of ALS, such as therapies that restore dysfunctional cellular waste clearance, manage overactive neurons, and eliminate toxic proteins. Through its advanced antisense oligonucleotides and small molecule programs, QurAlis seeks to halt disease progression and significantly improve patient outcomes for those affected by ALS.

Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

Faro Health is a developer of a cloud-based medical platform that aims to standardize, automate, and streamline the challenges associated with clinical trials. The company's innovative platform utilizes an integrated clinical development environment, which simplifies the design and authoring processes of complex clinical studies. By leveraging advanced digital protocols, Faro Health provides clinical researchers with in-context, intuitive insights throughout the authoring process. This approach allows researchers to optimize their study designs by reducing the administrative burden of clinical protocols, enabling them to concentrate on the critical decisions that enhance clinical value.

Folx Health is a telehealth platform established in 2020, based in Boston, Massachusetts, that specializes in providing digital healthcare services for the LGBTQIA+ community. The company focuses on creating a medical service marketplace tailored to the needs of queer and trans individuals, offering access to a network of specialized clinicians. Folx Health's services include gender-affirming hormone therapy, sexual health care, fertility testing, and general medical services. The platform emphasizes discreet delivery of at-home kits for medications, labs, and supplies, enabling users to manage their health without the barriers and stigma often found in traditional healthcare settings.

Capstan Therapeutics is a biotechnology company focused on advancing precision in vivo cell engineering to create therapeutics for various disease categories that have unmet or underserved clinical needs. The company specializes in expanding the therapeutic potential of RNA-based therapies through proprietary targeted delivery systems. Their platform utilizes targeted lipid nanoparticles to enhance off-the-shelf immunotherapies, providing tight control over dosage and activity of engineered cells. This approach aims to develop transformative products for conditions such as oncology, fibrosis, and inflammation-related diseases.

Amplifire is a company that specializes in developing an online learning platform designed to enhance individual performance and knowledge retention. The platform employs advanced learning algorithms and knowledge analytics to deliver measurable results in various sectors, including education, healthcare, and corporate environments. By focusing on diagnostic capabilities, Amplifire aims to empower users to learn effectively and apply their skills in real-world scenarios, ultimately enabling organizations to thrive in competitive markets. The company's innovative approach to learning supports individuals in reaching their highest potential while improving overall performance in their respective fields.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Tessa Therapeutics is a biotechnology company specializing in T cell therapy aimed at treating cancer, particularly solid tumors and lymphoma. The company focuses on developing both autologous and allogeneic cell therapies, including virus-specific T-cells and CAR T cells. Tessa Therapeutics aims to harness the body's anti-viral immune response to target and eliminate cancer cells, thereby transforming cancer treatment and enhancing the quality of life for patients. Through its innovative platform, Tessa Therapeutics is committed to advancing therapeutic options for healthcare providers and improving patient outcomes in the fight against cancer.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Seismic Therapeutic is a biotechnology company focused on advancing immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its proprietary IMPACT™ platform, Seismic Therapeutic addresses critical challenges in the development of biologics by combining machine learning with structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies for patients more efficiently. The company is developing a pipeline of biologics specifically targeting adaptive immune system dysregulation to treat various autoimmune diseases.

Dewpoint Therapeutics, Inc. is a Boston-based biotech company focused on the research and development of biomolecular condensates, aiming to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunological conditions, cardiovascular issues, women's health, and viral infections. Founded in 2018, the company utilizes a proprietary platform that combines experimental techniques with machine-learning-based image analysis to visualize and study biomolecular condensates. This technology includes a collection of genetically engineered cell lines designed to track condensates and mitigate harmful protein sequestration. By leveraging its advanced capabilities, Dewpoint Therapeutics seeks to address unmet medical needs and enhance drug discovery across multiple therapeutic areas, collaborating with leading academic and pharmaceutical partners to further its mission.

76Bio is a biotechnology company founded in 2020 and based in New York, focused on developing innovative therapies for patients with life-threatening diseases. The company specializes in creating targeted protein degraders, a novel approach that aims to degrade or break down unneeded proteins in the body. By leveraging advanced biotechnology, 76Bio seeks to deliver transformational therapies that address critical medical needs and improve patient outcomes through next-generation treatments.

Ankyra is a biotech company focused on developing anchored immunotherapy to enhance cancer treatment. The company's innovative approach addresses the challenges associated with traditional cytokine therapeutics, which often face limitations due to widespread immune activation and toxicity when administered systemically. Ankyra utilizes its Anchored Immunotherapy Platform to create ANK-101, a stable complex that combines a modified IL-12 cytokine with an FDA-approved adjuvant, aluminum hydroxide, which helps to retain the cytokine's potent activity at the tumor site. This localized delivery results in targeted inflammation that activates an anti-tumor immune response while minimizing adverse effects. Ankyra aims to optimize the efficacy and safety of its therapies, ultimately improving treatment outcomes for cancer patients.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

OM1, Inc. is a digital health company based in Boston, Massachusetts, that specializes in developing a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform enables hospitals and health systems to fulfill requirements related to patient-reported and clinical outcomes, particularly within value-based care programs and bundle payments. By integrating predictive and prescriptive analytics, OM1's technology helps mitigate risks, lower costs, and enhance the understanding of healthcare outcomes across the care continuum. The company synthesizes and enriches clinical data to provide actionable insights that improve clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014, OM1 leverages a team of scientists, clinical experts, and software engineers to address the complexities of healthcare results.

Muna Therapeutics is a private biopharmaceutical company focused on discovering and developing therapies aimed at slowing or halting the progression of neurodegenerative diseases such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis. The company is dedicated to identifying innovative medicines that preserve cognitive functions and enhance resilience in individuals affected by these conditions. By prioritizing the development of suitable therapeutics, Muna Therapeutics aims to improve recovery outcomes for patients suffering from neurodegenerative diseases.

Wellthy, Inc. is a family care concierge service based in New York, established in 2014. The company specializes in assisting individuals and families managing complex care situations, particularly those involving chronic illnesses, aging-related issues, or disabilities. Wellthy connects families with dedicated Care Coordinators who help navigate the logistical and administrative challenges of caregiving. This includes organizing appointments, managing contacts, and storing essential documents. The service is designed to support families dealing with a range of health conditions, such as dementia, diabetes, heart disease, and cancer, as well as those requiring assistance with childcare and special needs. Through its platform, Wellthy aims to alleviate the burden of care management, allowing families to focus on their loved ones’ well-being.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra focuses on creating orally administered dosage forms that provide sustained drug release for extended periods, ranging from a week to a month, while temporarily residing in the stomach. The company aims to address various therapeutic areas, including Alzheimer's, cardiovascular and metabolic diseases, psychiatric disorders, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By developing these innovative therapies, Lyndra seeks to enhance medication adherence, improve health outcomes, and ultimately reduce healthcare costs.

Kojin Therapeutics, founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, focuses on advancing a drug discovery platform that links complex cell states to established biochemical processes, specifically ferroptosis, which involves iron-dependent cell death. This innovative approach enables the development of targeted therapies for a wide range of challenging diseases that are often difficult to treat. The company's biology platform aims to identify disease-specific targets, ensuring that patients receive effective treatments tailored to their specific conditions. Kojin Therapeutics is supported by a diverse group of investors, including Polaris Partners, Newpath Partners, and AbbVie, among others.

Faro Health is a developer of a cloud-based medical platform that aims to standardize, automate, and streamline the challenges associated with clinical trials. The company's innovative platform utilizes an integrated clinical development environment, which simplifies the design and authoring processes of complex clinical studies. By leveraging advanced digital protocols, Faro Health provides clinical researchers with in-context, intuitive insights throughout the authoring process. This approach allows researchers to optimize their study designs by reducing the administrative burden of clinical protocols, enabling them to concentrate on the critical decisions that enhance clinical value.

Thirty Madison, Inc. is a digital health company based in Astoria, New York, that focuses on providing specialized healthcare solutions for patients with chronic conditions. Founded in 2016, the company operates several condition-specific brands, including Keeps, which offers a subscription-based service for men’s hair loss prevention; Cove, which provides online consultations and prescriptions for migraine treatment; Picnic, targeting allergies; Facet for skin conditions; and NURX for sexual health. Each brand is designed to address the unique needs of its community, offering personalized treatments and support. Thirty Madison emphasizes a human-centered approach, empowering individuals with accessible and effective healthcare solutions tailored to their ongoing conditions.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

Akili Interactive Labs, Inc., established in 2011 and headquartered in Boston, Massachusetts, specializes in developing digital medicine solutions. The company's core business involves creating video game-based technology to assess and enhance cognitive abilities. Akili's broad pipeline focuses on treating cognitive deficiencies and improving symptoms associated with various medical conditions, such as ADHD, MDD, ASD, and inflammatory diseases.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Cohere Health, Inc. is a healthcare technology company based in Boston, Massachusetts, founded in 2019. The company specializes in developing a platform that enhances collaboration among healthcare stakeholders, including patients, providers, and payers. Cohere Health focuses on improving the efficiency and effectiveness of healthcare delivery by simplifying complex processes through technology. Its primary offering is an intelligent prior authorization solution that is configurable to meet the specific needs of different health plans. This solution can be implemented as a fully outsourced utilization management service, utilizing artificial intelligence, machine learning, and real-time analytics to automate the prior authorization process. By doing so, Cohere Health aims to facilitate seamless communication and guide quality care throughout the patient journey, ultimately improving patient outcomes.

Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

Tausight, Inc. is a software company founded in 2018 and headquartered in Sudbury, Massachusetts, with an additional office in San Francisco, California. The company focuses on mitigating healthcare cyber incidents related to patient data theft, addressing a critical need for chief information officers and chief information security officers in the healthcare sector. Tausight's software employs machine learning techniques to enhance the confidentiality, integrity, and availability of patient health information (PHI). By implementing a proactive risk management approach, the software aims to improve patient care, clinician satisfaction, regulatory compliance, and foster innovation within healthcare organizations.

Livara Health is a provider of non-operative, personalized treatment for musculoskeletal conditions, focusing specifically on back and neck problems. The company has developed an orthopedic care management platform that offers a data-driven, non-invasive back pain program. This program assesses patients' needs and customizes a comprehensive six-week treatment plan aimed at delivering relief. Patients receive physical therapy coaching, which can be accessed both online and onsite, to support their progress throughout the program. Livara Health's approach allows individuals to manage their musculoskeletal issues effectively without the need for surgical intervention.

Folx Health is a telehealth platform established in 2020, based in Boston, Massachusetts, that specializes in providing digital healthcare services for the LGBTQIA+ community. The company focuses on creating a medical service marketplace tailored to the needs of queer and trans individuals, offering access to a network of specialized clinicians. Folx Health's services include gender-affirming hormone therapy, sexual health care, fertility testing, and general medical services. The platform emphasizes discreet delivery of at-home kits for medications, labs, and supplies, enabling users to manage their health without the barriers and stigma often found in traditional healthcare settings.

Covetrus is a company focused on enhancing veterinary care through a combination of production, distribution, and management services. It specializes in supply chain solutions, veterinary practice management software, and prescription management, all aimed at improving health and financial outcomes for veterinary practices. By providing these integral services, Covetrus supports the well-being of animals and the professionals who care for them, contributing to advancements in the field of veterinary medicine.

Sesh Therapy Incorporated is a mental health company that delivers online group support through its mobile application. Founded in 2020 and headquartered in San Francisco, California, Sesh provides a range of sessions led by qualified mental health professionals, making mental healthcare more accessible and affordable compared to traditional therapy appointments. The platform aims to connect individuals seeking support in a collaborative environment, enhancing the overall mental health experience.

FidoCure is dedicated to advancing cancer care for dogs through AI-driven precision medicine. The company utilizes data from naturally occurring canine cancers, combining next-generation sequencing with clinical insights to create the largest proprietary learning database for canine oncology. FidoCure offers personalized medicine services that go beyond traditional chemotherapy and radiation, collecting tissue samples for DNA sequencing to identify genetic mutations impacting treatment. This approach allows for the development of targeted therapies aimed at effectively attacking cancer cells. By bridging the gap between human and veterinary oncology, FidoCure enhances comparative oncology, improving treatment outcomes for both pets and humans while addressing a significant unmet need in canine cancer care.

Primmune Therapeutics, Inc. is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in developing small molecule, orally administered toll-like receptor 7 (TLR7) agonists aimed at enhancing innate immunity for cancer immunotherapy. Its TLR7 agonists are designed to stimulate the immune system by producing cytokines and chemokines that boost cellular responses and activate natural killer cells. This approach is intended to complement existing cancer treatments, such as checkpoint inhibitors, improving overall response rates and treatment durability. Primmune Therapeutics' innovative therapies target both acute and chronic viral infections, as well as metastatic diseases, while also promoting B-cell proliferation and activation.

Dewpoint Therapeutics, Inc. is a Boston-based biotech company focused on the research and development of biomolecular condensates, aiming to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunological conditions, cardiovascular issues, women's health, and viral infections. Founded in 2018, the company utilizes a proprietary platform that combines experimental techniques with machine-learning-based image analysis to visualize and study biomolecular condensates. This technology includes a collection of genetically engineered cell lines designed to track condensates and mitigate harmful protein sequestration. By leveraging its advanced capabilities, Dewpoint Therapeutics seeks to address unmet medical needs and enhance drug discovery across multiple therapeutic areas, collaborating with leading academic and pharmaceutical partners to further its mission.

Neogene Therapeutics, Inc., founded in 2018 and based in New York, develops innovative T cell therapies aimed at treating cancer. The company specializes in creating personalized engineered T cells that target mutated proteins, known as neo-antigens, found in cancer cells as a result of DNA mutations. By leveraging advanced technologies, Neogene isolates neo-antigen specific T cell receptor genes from tumor biopsies, which are routinely collected during cancer treatment. These tumor-infiltrating lymphocytes often express T cell receptors that can recognize and attack cancer cells displaying neo-antigens. Utilizing state-of-the-art DNA sequencing, synthesis, and genetic screening, Neogene's proprietary platform enables the identification of these specific T cell receptors with high sensitivity and at scale, ultimately enhancing the efficacy of cancer treatments.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on the discovery and development of innovative cancer therapeutics. Established in 2017, the company aims to address historically challenging cancer targets through precision medicine. Its primary product candidates include entospletinib, a selective inhibitor of spleen tyrosine kinase intended for acute myeloid leukemia patients, and KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for treating MYC-amplified solid tumors. Kronos Bio employs advanced technologies, such as high-throughput small-molecule microarrays and targeted protein degradation, to identify potent and selective compounds that target dysregulated transcription factors and other key drivers of oncogenic signaling.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

2 out of 3 men will start to lose their hair by the age of 35 - but the earlier you take action, the more hair you keep. Keeps is a full-service healthcare company focused exclusively on helping men keep their hair. From expert diagnosis to affordable treatment, patient support to education, Keeps provides a regimen specific to each customer's condition through a seamless digital experience, allowing men to manage hair loss from start to finish. Keeps’ licensed physicians review each customer's information in order to identify and prescribe a unique treatment plan of FDA-approved products, and we sell them at half the price customers would pay at their local pharmacy. With Keeps, customers receive exactly what they need, and nothing they don’t. Keeps is the first brand from Thirty Madison, which is rebuilding the healthcare experience for the modern consumer.

Thirty Madison, Inc. is a digital health company based in Astoria, New York, that focuses on providing specialized healthcare solutions for patients with chronic conditions. Founded in 2016, the company operates several condition-specific brands, including Keeps, which offers a subscription-based service for men’s hair loss prevention; Cove, which provides online consultations and prescriptions for migraine treatment; Picnic, targeting allergies; Facet for skin conditions; and NURX for sexual health. Each brand is designed to address the unique needs of its community, offering personalized treatments and support. Thirty Madison emphasizes a human-centered approach, empowering individuals with accessible and effective healthcare solutions tailored to their ongoing conditions.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

Ankyra is a biotech company focused on developing anchored immunotherapy to enhance cancer treatment. The company's innovative approach addresses the challenges associated with traditional cytokine therapeutics, which often face limitations due to widespread immune activation and toxicity when administered systemically. Ankyra utilizes its Anchored Immunotherapy Platform to create ANK-101, a stable complex that combines a modified IL-12 cytokine with an FDA-approved adjuvant, aluminum hydroxide, which helps to retain the cytokine's potent activity at the tumor site. This localized delivery results in targeted inflammation that activates an anti-tumor immune response while minimizing adverse effects. Ankyra aims to optimize the efficacy and safety of its therapies, ultimately improving treatment outcomes for cancer patients.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis employs proprietary platforms and biomarkers to create precision medicines that target genetically validated disease-causing alterations. The company’s pipeline includes innovative treatments aimed at specific subtypes of ALS, such as therapies that restore dysfunctional cellular waste clearance, manage overactive neurons, and eliminate toxic proteins. Through its advanced antisense oligonucleotides and small molecule programs, QurAlis seeks to halt disease progression and significantly improve patient outcomes for those affected by ALS.

Folx Health is a telehealth platform established in 2020, based in Boston, Massachusetts, that specializes in providing digital healthcare services for the LGBTQIA+ community. The company focuses on creating a medical service marketplace tailored to the needs of queer and trans individuals, offering access to a network of specialized clinicians. Folx Health's services include gender-affirming hormone therapy, sexual health care, fertility testing, and general medical services. The platform emphasizes discreet delivery of at-home kits for medications, labs, and supplies, enabling users to manage their health without the barriers and stigma often found in traditional healthcare settings.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

Amagma Therapeutics is a biotechnology company founded in 2019 and based in Waltham, Massachusetts. The company focuses on the discovery and development of antibody therapeutics aimed at addressing inflammatory diseases caused by enzyme hyperactivity. Specifically, Amagma's therapies target overactive extracellular proteases, which lead to tissue damage and contribute to widespread inflammatory responses. By developing these innovative treatments, Amagma aims to enhance therapeutic efficacy while ensuring patient safety in the management of human diseases linked to enzyme dysfunction.

Umbulizer is a manufacturer of low-cost, portable breathing devices aimed at reducing patient fatalities, particularly in resource-limited settings. The company's flagship product, UMV-001, is designed to deliver continuous ventilation, making it suitable for emergency situations where traditional ventilators may not be available. Their devices are user-friendly and can be wirelessly monitored, enabling medical practitioners to effectively use them in critical care scenarios. By addressing the urgent demand for life-saving ventilators, Umbulizer contributes significantly to improving patient outcomes in challenging healthcare environments.

OM1, Inc. is a digital health company based in Boston, Massachusetts, that specializes in developing a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform enables hospitals and health systems to fulfill requirements related to patient-reported and clinical outcomes, particularly within value-based care programs and bundle payments. By integrating predictive and prescriptive analytics, OM1's technology helps mitigate risks, lower costs, and enhance the understanding of healthcare outcomes across the care continuum. The company synthesizes and enriches clinical data to provide actionable insights that improve clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014, OM1 leverages a team of scientists, clinical experts, and software engineers to address the complexities of healthcare results.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on the discovery and development of innovative cancer therapeutics. Established in 2017, the company aims to address historically challenging cancer targets through precision medicine. Its primary product candidates include entospletinib, a selective inhibitor of spleen tyrosine kinase intended for acute myeloid leukemia patients, and KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for treating MYC-amplified solid tumors. Kronos Bio employs advanced technologies, such as high-throughput small-molecule microarrays and targeted protein degradation, to identify potent and selective compounds that target dysregulated transcription factors and other key drivers of oncogenic signaling.

Ajax Health, established in 2017, is a venture capital firm headquartered in Menlo Park, California, with an additional office in New York City. The company specializes in investing in innovative medical device companies, digital health, healthcare services, and biotechnology across all stages of a company's lifecycle. Ajax Health seeks to accelerate medical innovation by providing capital and strategic capabilities to address major healthcare issues.

Quartet Health is a New York-based company that develops a cloud-based platform designed to enhance communication and collaboration between medical providers and behavioral health providers for patient care. Founded in 2014, Quartet's platform works with health plans and systems to deliver actionable insights and reports on behavioral health conditions, aiming to improve patient outcomes. The platform also offers tools for patient self-management and ensures that mental health care is tailored to individual preferences and clinical needs, while being integrated with the broader healthcare experience and insurance coverage.

Blackthorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, founded in 2013. The company focuses on developing precision medicine for neurobehavioral disorders, utilizing advances in computational and clinical neuroscience. By leveraging its proprietary computational platform, Blackthorn aims to address historical challenges in drug discovery by targeting dysfunctional brain circuits. This approach enables the identification of novel drug candidates and biologically-based patient subgroups that are most likely to respond to specific treatments. Through its innovative strategies, Blackthorn seeks to enhance the precision of therapeutic interventions for disorders of the central nervous system, ultimately improving patient outcomes.

Ajax Health, established in 2017, is a venture capital firm headquartered in Menlo Park, California, with an additional office in New York City. The company specializes in investing in innovative medical device companies, digital health, healthcare services, and biotechnology across all stages of a company's lifecycle. Ajax Health seeks to accelerate medical innovation by providing capital and strategic capabilities to address major healthcare issues.

Africa Healthcare Network (AHN) is a pioneering provider of dialysis services in Sub-Saharan Africa, establishing the first chain of dialysis centers in the region. The organization focuses on delivering high-quality, life-saving dialysis treatment at affordable prices, addressing the critical shortage of accessible care for patients suffering from Acute Kidney Injury (AKI) and End-Stage Renal Disease (ESRD). With a commitment to improving healthcare in a region faced with limited resources and a rising prevalence of Chronic Kidney Disease (CKD) due to urbanization and lifestyle diseases, AHN combines global technical expertise with practical operational experience. The organization aims to enhance the quality of care while reducing costs for patients by securing high-quality equipment, training healthcare professionals, and optimizing operational efficiency. Operating in Rwanda, Tanzania, and Kenya, AHN seeks to increase patient access to essential dialysis services, fostering better health outcomes and providing a sustainable business model.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra focuses on creating orally administered dosage forms that provide sustained drug release for extended periods, ranging from a week to a month, while temporarily residing in the stomach. The company aims to address various therapeutic areas, including Alzheimer's, cardiovascular and metabolic diseases, psychiatric disorders, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By developing these innovative therapies, Lyndra seeks to enhance medication adherence, improve health outcomes, and ultimately reduce healthcare costs.

KenSci Inc. is a healthcare technology company that specializes in developing a machine learning platform aimed at improving risk prediction for healthcare providers and payers. Founded in 2015 and headquartered in Seattle, Washington, with additional offices in Hyderabad and Singapore, KenSci's platform integrates and analyzes data from various sources, including clinical records, claims, and patient-generated information. This enables healthcare organizations to identify clinical, financial, and operational risks, allowing for earlier interventions that can save costs and improve patient outcomes. The platform offers a library of pre-built models and modular solutions, facilitating seamless integration into existing workflows to enhance hospital operations and care coordination. By leveraging Explainable AI, KenSci ensures that its risk-based predictions are both efficient and accountable, ultimately supporting the delivery of better healthcare.

Candesant Biomedical, Incorporated is a medical device company focused on developing innovative solutions for excessive sweating and hyperhidrosis. Founded in 2015 and based in San Francisco, California, the company offers a proprietary device known as CDX-101, which utilizes water-activated technology to target and inactivate active sweat glands without causing discomfort to patients. The technology operates on the principle that alkali metals generate energy upon contact with water, allowing for precise energy delivery to the specific areas where sweat glands are most active. This approach not only aims to reduce excessive sweating but also helps inhibit bacterial growth associated with hyperhidrosis, providing a significant improvement in the quality of life for affected individuals.

Dewpoint Therapeutics, Inc. is a Boston-based biotech company focused on the research and development of biomolecular condensates, aiming to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunological conditions, cardiovascular issues, women's health, and viral infections. Founded in 2018, the company utilizes a proprietary platform that combines experimental techniques with machine-learning-based image analysis to visualize and study biomolecular condensates. This technology includes a collection of genetically engineered cell lines designed to track condensates and mitigate harmful protein sequestration. By leveraging its advanced capabilities, Dewpoint Therapeutics seeks to address unmet medical needs and enhance drug discovery across multiple therapeutic areas, collaborating with leading academic and pharmaceutical partners to further its mission.

Genetic Foresight’s mission is to prevent adverse drug reactions, increase therapeutic success rates, and minimize healthcare costs by enabling clinicians to make informed decisions. Founded in 2016, Genetic Foresight provides a genetic test that sequences targeted segments of patients' genomes as well as a comprehensive prescription decision platform that incorporates drug-genome, drug-drug, drug-disease, personal health, lifestyle, and medical and family histories to predict drug response. This allows the clinician to more safely and effectively prescribe medication based on the patient. The report is updated based on newly generated research, newly created drugs, and newly prescribed drugs, making it a lifetime test.

Wellthy, Inc. is a family care concierge service based in New York, established in 2014. The company specializes in assisting individuals and families managing complex care situations, particularly those involving chronic illnesses, aging-related issues, or disabilities. Wellthy connects families with dedicated Care Coordinators who help navigate the logistical and administrative challenges of caregiving. This includes organizing appointments, managing contacts, and storing essential documents. The service is designed to support families dealing with a range of health conditions, such as dementia, diabetes, heart disease, and cancer, as well as those requiring assistance with childcare and special needs. Through its platform, Wellthy aims to alleviate the burden of care management, allowing families to focus on their loved ones’ well-being.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Gauss Surgical, Inc. is a medical technology company that specializes in real-time blood monitoring solutions to enhance patient outcomes in surgical and obstetric settings. Founded in 2011 and headquartered in Los Altos, California, Gauss Surgical develops the Triton system, which includes various models suited for different medical needs. Triton assists healthcare professionals in monitoring and estimating blood loss during procedures, allowing for timely intervention in cases of hemorrhage. The system offers objective metrics for blood loss, thereby facilitating better clinical decision-making regarding transfusions. Serving the healthcare sector primarily in the United States, Gauss Surgical's products are designed to integrate seamlessly into existing medical practices, using sophisticated algorithms and HIPAA-compliant technology to deliver accurate monitoring in real time.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on the agriculture industry through the development of biological products. Founded in 2012, AgBiome leverages its expertise in plant-associated microbes and modern genomics to create innovative solutions aimed at enhancing plant health, pest resistance, and crop yields. The company addresses critical agricultural challenges, including soil-borne diseases, insects, and nematodes, by offering fungicides and a platform that identifies and screens diverse microbial strains. AgBiome collaborates with prominent agricultural partners to accelerate discovery processes and broaden the reach of its sustainable products in global markets. With a dedicated team of over 85 employees and a state-of-the-art laboratory and greenhouse facility, AgBiome is committed to improving food production responsibly.

Ajax Health, established in 2017, is a venture capital firm headquartered in Menlo Park, California, with an additional office in New York City. The company specializes in investing in innovative medical device companies, digital health, healthcare services, and biotechnology across all stages of a company's lifecycle. Ajax Health seeks to accelerate medical innovation by providing capital and strategic capabilities to address major healthcare issues.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

OM1, Inc. is a digital health company based in Boston, Massachusetts, that specializes in developing a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform enables hospitals and health systems to fulfill requirements related to patient-reported and clinical outcomes, particularly within value-based care programs and bundle payments. By integrating predictive and prescriptive analytics, OM1's technology helps mitigate risks, lower costs, and enhance the understanding of healthcare outcomes across the care continuum. The company synthesizes and enriches clinical data to provide actionable insights that improve clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014, OM1 leverages a team of scientists, clinical experts, and software engineers to address the complexities of healthcare results.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Quentis Therapeutics, Inc. is a biotechnology company founded in 2016 and based in New York, specializing in the development of cancer immunotherapies. The company's innovative therapeutics focus on modulating endoplasmic reticulum (ER) stress response pathways within the tumor microenvironment. By targeting these pathways, Quentis Therapeutics aims to enhance the immune system's ability to combat cancer, thereby providing patients with access to novel treatment options. The company's approach seeks to translate cutting-edge biological insights into effective therapeutic strategies that can improve anti-tumor immunity.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Quartet Health is a New York-based company that develops a cloud-based platform designed to enhance communication and collaboration between medical providers and behavioral health providers for patient care. Founded in 2014, Quartet's platform works with health plans and systems to deliver actionable insights and reports on behavioral health conditions, aiming to improve patient outcomes. The platform also offers tools for patient self-management and ensures that mental health care is tailored to individual preferences and clinical needs, while being integrated with the broader healthcare experience and insurance coverage.